Vaxcyte, Inc. — Director's Dealing 2021

Jan 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-01-20

Reporting Person: Wassil Jim (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-20	Common Stock	M	3000	$2.42	Acquired	19381	Direct
2021-01-20	Common Stock	S	3000	$25.50	Disposed	16381	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-20	Stock Option (right to buy)	$2.42	M	3000	Disposed	2029-12-16	Common Stock (3000)	Direct

Footnotes

F1: Includes 1,562 shares acquired under the Employment Stock Purchase Plan on November 17, 2020.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.50 to $25.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.